D
Douglas C. Wolf
Researcher at Cleveland Clinic
Publications - 86
Citations - 6417
Douglas C. Wolf is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Ulcerative colitis & Adalimumab. The author has an hindex of 23, co-authored 84 publications receiving 5527 citations.
Papers
More filters
Journal ArticleDOI
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn,Gert Van Assche,Walter Reinisch,Jean-Frederic Colombel,Geert R. D'Haens,Douglas C. Wolf,Martina Kron,Mary Beth Tighe,Andreas Lazar,Roopal Thakkar +9 more
TL;DR: Adalimumab was safe and more effective than placebo in inducing and maintaining clinical remission in patients with moderate-to-severe ulcerative colitis who did not have an adequate response to conventional therapy with steroids or immunosuppressants.
Journal ArticleDOI
Adalimumab for Maintenance Treatment of Crohn's Disease: Results of the CLASSIC II Trial
William J. Sandborn,Stephen B. Hanauer,Paul Rutgeerts,Richard N. Fedorak,Milan Lukas,Donald G. MacIntosh,Remo Panaccione,Douglas C. Wolf,J. D. Kent,Barry Bittle,Ju Li,Paul F. Pollack +11 more
TL;DR: Adalimumab induced and maintained clinical remission for up to 56 weeks in patients with moderate to severe Crohn’s disease naive to anti-TNF treatment in a follow-on randomised controlled trial.
Journal ArticleDOI
Natalizumab for the Treatment of Active Crohn’s Disease: Results of the ENCORE Trial
Stephan R. Targan,Brian G. Feagan,Richard N. Fedorak,Bret A. Lashner,Remo Panaccione,Daniel H. Present,Martina E. Spehlmann,Paul Rutgeerts,Zsolt Tulassay,Miroslava Volfova,Douglas C. Wolf,Chito Hernandez,Jeffrey D. Bornstein,William J. Sandborn +13 more
TL;DR: Response and remission rates for natalizumab were superior to those for placebo at Weeks 4, 8, and 12, demonstrating the early and sustained efficacy of natalIZumab as induction therapy in patients with elevated C-reactive protein and active Crohn's disease.
Journal ArticleDOI
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
Paul Rutgeerts,Robert H. Diamond,Mohan Bala,Allan Olson,Gary R. Lichtenstein,Weihang Bao,Kamlesh Patel,Douglas C. Wolf,Michael Safdi,Jean-Frederic Colombel,Bret A. Lashner,Stephen B. Hanauer +11 more
TL;DR: Scheduled infliximab maintenance therapy resulted in more improvement in mucosal ulceration and in higher rates of mucosal healing, and there was a numerical trend for patients with better mucosal Healing to have a lower rate of Crohn's disease-related hospitalizations.
Journal ArticleDOI
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
Paul Rutgeerts,Gert Van Assche,William J. Sandborn,Douglas C. Wolf,Karel Geboes,Jean-Frederic Colombel,Walter Reinisch,Ashok Kumar,Andreas Lazar,Anne Camez,K Lomax,Paul F. Pollack,Geert R. D'Haens +12 more
TL;DR: Following induction therapy with adalimumab, patients with moderately to severely active CD who continue to receive adal optimumab are more likely to achieve mucosal healing than those given placebo.